trial · primary record
Atezolizumab
Hepatocellular Carcinoma
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 342 |
| Primary completion | 2029-02-01 |
| Primary endpoint | TACE Progression-Free Survival (TACE PFS) as Determined by Investigator |
| Registry ID | NCT04712643 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:07.204Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04712643
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.